Infectin Viral Transduction Enhancer


Infectin serves as a viral infection enhancer and increases infectivity rates by 5 to 20 fold.

Size 200 µL, 500 µL, 1 mL, 5 x 1mL
SKU: N/A Categories: , Tags: , , , ,

Product Description

A cutting-edge technology in virology research

InfectinTM is a viral infection enhancer designed to facilitate viral penetration of the cortical actin barrier, thereby greatly enhancing productive viral infection. InfectinTM can be used to facilitate the infection of a variety of host cells by different viruses and viral vectors. InfectinTM can enhance viral infection rates by 5 to 20 fold. Virongy developed InfectinTM based on the scientific theory that the actin cytoskeleton is a natural barrier for viral entry and post-entry intracellular migration (Yoder et al., Cell, 2008, 134:782).


  • Enhancing lenti- or retroviral transduction of target cells
  • Enhancing infection rates of other enveloped viruses
  • Facilitating recovery of infectious viruses from cell or tissue cultures
  • Facilitating anti-viral drug screening efficiency



  • Once thawed, InfectinTM should be stored at 4oC, and is stable for 3 months.
  • Do not re-freeze and do not leave InfectinTM at room temperature.
  • InfectinTM viral infection enhancer works with most cell lines to enhance viral infection. On average, InfectinTM enhances productive viral infection by 5- to 30-fold*.
  • InfectinTM is formulated at 10X concentration. For best results, when using InfectinTM for the first time, start with a higher concentration (final Infectin concentration may be 2X or 3X). The lowest effective dosage can be determined through a titration experiment (final InfectinTM concentration may be as low as 1X).

(*The degree of enhancement is affected by the type of virus and cells. Enhancement is strongest for enveloped viruses entering cells via membrane fusion.)


InfectinTM enhances lentiviral transduction of Hep G2 cells:

Hep G2 cells were transduced with lenti-GFP vector in the presence or absence of Infectin



Infectin – MSDS
Infectin – Protocol 

Selected Publications

Selected publications from our users

Yoder, A., Yu, D., Dong, L., Iyer, S. R., Xu, X., Kelly, J., Liu, J., Wang, W., Vorster, P. J., Agulto, L., Stephany, D. A., Cooper, J. N., Marsh, J. W., & Wu, Y. (2008). HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell, 134(5), 782–792.

DeMarino, C., Cowen, M., Pleet, M.L., Pinto, D.O., Khatkar, P., Erickson, J., Docken, S.S., Russell, N., Reichmuth, B., Phan, T., et al. (2020). Differences in Transcriptional Dynamics Between T-cells and Macrophages as Determined by a Three-State Mathematical Model. Sci Rep 10, 2227.

Fu, Y., He, S., Waheed, A.A., Dabbagh, D., Zhou, Z., Trinite, B., Wang, Z., Yu, J., Wang, D., Li, F., et al. (2020). PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells. Proc Natl Acad Sci U S A.

He, S., Hetrick, B., Dabbagh, D., Akhrymuk, I.V., Kehn-Hall, K., Freed, E.O., and Wu, Y. (2020). PSGL-1 blocks SARS-CoV-2 S protein-mediated virus attachment and infection of target cells. bioRxiv.